Sango-an, Leonardo D.
HRN: 22-28-08 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/01/2022
CO-AMOXICLAV 625MG (TAB)
12/01/2022
12/07/2022
PO
625mg
BID
Infected Tophi
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes